Thulium Laser and Growth Factors for Androgenetic Alopecia - a Prospective, Clinical Study
Androgenetic alopecia (AGA) is a common cause of hair loss worldwide. It mainly affects the frontal and parietal regions of the scalp in up to 70 % of men and 40 % of women and has a significant negative psychological and emotional impact on those affected. Various therapies are currently approved for the treatment of AGA in men and women, including topical minoxidil, topical or systemic finasteride, platelet-rich plasma and hair transplantation. In addition to these pharmacological and surgical interventions, laser therapies including thulium laser with growth factors have gained popularity. Despite the clinical use of the thulium laser with growth factors in combination with LED phototherapy, there are only a few studies to date that have adequately investigated the objective and patient-side benefits of this therapy.
• Men and women aged 18 and over
• Good general health, no relevant previous illnesses
• Presence of an AGA
• Cognitive ability and willingness to give consent (informed consent)
• Be willing and able to attend follow-up visits